FierceHealthcareFierceHealthITFierceHealthFinanceFierceEMRHospital ImpactFierceMobileHealthcare   FiercePharma
Syndicate content

Vytorin news from FierceHealthcare

News

Best-selling branded drugs of '08; BCBS of TN uses interactive calls for wellness campaign;

> What were the best-selling branded drugs in the world last year? Our sister publication FiercePharma has the scoop. List > BlueCross BlueShield of Tennessee is using personalized interactive... Read more...

Trend: Providers increase use of CT scans

To date, CT scans have never been proved in large medical studies to be better than other forms of imaging. Worse, they expose patients to larger doses of radiation than other scans, equivalent to... Read more...

Drugmakers agree to six-month DTC delay

Under fire over direct-to-consumer ads, which some Congressional legislators contend are misleading to consumers, pharmaceutical companies have agreed to voluntarily wait six months after drugs are... Read more...

ALSO NOTED: Demand for health IT pros to soar; Pharmas lobbying hard in DC; and much more...

> Industry researchers are predicting that it will take a huge increase in the volume of professionals available (more than 40,000) to meet the near-term demand for skilled health IT pros. Read more...

Reports suggest that Merck downplayed Vioxx risks

Another day, another report suggesting that a pharmaceutical company tried to bury data impugning the safety of one of its products. This time, a study has been published in The Journal of the... Read more...

FDA says Glaxo didn't report Avandia data

According to a new letter from the agency, GlaxoSmithKline didn't turn over post-marketing data about Avandia to the FDA, a lack of disclosure that looks pretty unfortunate given subsequent reports... Read more...

ALSO NOTED: UnitedHealth stands behind Vytorin; Groups release diabetes management toolkit; and much more...

> Despite the controversy over its effectiveness, UnitedHealth Group has said that it will continue to cover Vytorin has it has in the past. Read more...

Congress says drugmakers held back Vytorin data

Cholesterol drug Vytorin--and makers Merck and Schering-Plough--have been under fire for months since a study suggested that the expensive combo med works no better than much less costly Zocor.... Read more...